Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to next-generation AR-directed therapies. ARN-509-001 was a phase I/II study that evaluated apalutamide activity in castration-resistant prostate cancer (CRPC). Here, we evaluated the type and frequency of 11 relevant AR-LBD mutations in apalutamide-treated CRPC patients.

中文翻译：

---

阿帕鲁胺治疗去势抵抗性前列腺癌患者的雄激素受体突变

雄激素受体（AR）配体结合域（LBD）中的突变，例如F877L和T878A，已与对下一代AR导向疗法的耐药性相关。ARN-509-001是一项I / II期研究，评估了去势抵抗性前列腺癌（CRPC）中阿帕鲁胺的活性。在这里，我们评估了阿帕鲁胺治疗的CRPC患者中11种相关AR-LBD突变的类型和频率。